Full-Time

Head of Liquid Product Management

Multiple Teams

Posted on 8/29/2025

Caris

Caris

1,001-5,000 employees

Provides AI-powered molecular insights for cancer

Compensation Overview

$210k - $230k/yr

Remote in USA

Remote

Position requires up to 50% travel.

Category
Product (1)
Requirements
  • Bachelor's degree from an accredited university.
  • 5+ years of prior people leadership experience required with a strong understanding of the oncology, pathology and/or liquid product diagnostic market.
  • Possess high degree of understanding the client relationship with Physicians, their needs, and how we can provide service and technology solutions for their oncology needs.
  • Proven success with large, global, brand marketers and agencies.
  • Passionate and engaging approach to working with internal and external partners.
  • Demonstrated decision making ability towards solving problems, while working under pressure and effectively communicating these solutions to co-workers and customers.
  • General understanding of business policies and practices.
  • Proficient in Microsoft Office Suite and Internet for business use.
Responsibilities
  • Meet or exceed company’s direct liquid product sales volume and revenue targets.
  • Develop area liquid product sales strategy to deliver against direct sales volume and revenue objectives.
  • Establish senior level relationships within key accounts.
  • Successfully build, train and manage a sales team to meet and exceed revenue objectives.
  • Provide consistent marketplace feedback to support development of sales strategy that achieves volume and revenue objectives.
  • Provide regular visibility for management and staff on industry trends, best practices, and competitive insights.
  • Build and foster strong cross-functional internal relationships to facilitate efficient processes for product development, pipeline management, compensation plans, sales reporting, and volume/revenue forecasting.
  • Maintain accurate and timely communication with VP, Liquid Product Management regarding all relevant regional information regarding revenue and advertiser relationships.
  • Sells Liquid Product services and technology to physicians.
  • Provides business solutions to physicians in the practice setting.
  • Analyze business opportunities and develop strategic sales plans for assigned territory.
  • Develop and maintain strong relationships with new and existing clients.
  • Utilize understanding of and experience discussing the healthcare payer environment and its impact on physicians and ancillary providers.
  • Negotiate sales contracts, which must be approved by the Senior Vice President prior to implementation.
  • Advises Senior Management Team on relevant client or market concerns.
  • Develops and maintains 'Core' knowledge of competitive products, services, technology solutions, and reimbursement/billing issues.
  • Provides necessary and appropriate post-sales service to accounts, utilizing each opportunity to discover and pursue additional business.
  • Establish and maintain open lines of communication with key personnel in assigned accounts as related to support on-going issues (i.e., installations, upgrades, persistent problems). Escalate support issues when customer satisfaction is jeopardized.
  • Maintain all assigned company assets including laptop computer, PDA, etc.
  • Submit all necessary paperwork, including travel itineraries, trip reports, activity reports, monthly reports, expenses, and service reports, as required, accurately and in a timely manner.
  • Demonstrates 'Core' level knowledge of oncology, technology solutions and competitive strategies through the use of company resources, on the job training, in-house literature, marketing material, and sales brochures.
  • Meet all assigned targets and goals set by management.
  • Provide meeting and trade show support as required.
  • Supports physicians with the complexity of the ordering and interpretation of the CMI platform, and QC report quality/accuracy which may require access to detailed protected health information (PHI). Engages with on-site hospital billing department to follow-up on specific claim details to support proper hospital payment, as appropriate.
  • Perform other related duties as assigned.
Desired Qualifications
  • MBA preferred.
  • Prior experience of leading leaders strongly preferred.

Caris Life Sciences provides molecular information to cancer patients, oncologists, researchers, and payors to guide personalized cancer care. Its core product uses molecular profiling and artificial intelligence to interpret a cancer’s molecular features at diagnosis, helping predict how the cancer may behave and which treatments are likely to work. The company differentiates itself by delivering a comprehensive, AI-assisted set of molecular insights across multiple stakeholders, translating complex genomic and other molecular data into actionable treatment guidance. Its goal is to improve cancer outcomes by enabling more precise, tailored therapy for each patient.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1996

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surged 79% to $216.2 million with positive $26.2 million adjusted EBITDA.
  • Secured $1.2 billion credit facilities from Blue Owl and Blackstone in 2026.
  • CodeAI platform powers seven AI insights trained on over 500,000 patient profiles.

What critics are saying

  • Foundation Medicine's FoundationOne CDx captures 65% NGS orders, eroding Caris market share.
  • Tempus xT assay diverts biopharma partnerships with 7 million real-world records.
  • 2025 False Claims Act settlement of $2.9 million exposes ongoing Medicare billing violations.

What makes Caris unique

  • Caris MI Clarity uses AI on H&E slides to predict early and late breast cancer recurrence risks.
  • Caris ChromoSeq combines whole genome and transcriptome sequencing for myeloid malignancies in seven days.
  • FDA approved MI Cancer Seek in November 2024 as companion diagnostic for Keytruda and Braftovi.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Caris who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Company Match

Employee Assistance Program

Pet Insurance

Legal Assistance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Apr 8th, 2026
Caris Life Sciences launches AI-powered tool to determine chemotherapy benefit or harm for NSCLC patients

Caris Life Sciences has launched an AI-driven molecular insight to help determine which non-small cell lung cancer patients benefit from adding chemotherapy to immunotherapy treatment, and which may be harmed by it. The signature uses Whole Exome Sequencing and Whole Transcriptome Sequencing combined with clinical data. The tool targets patients with driver-negative tumours expressing high PD-L1 levels. It first stratifies patients into higher versus standard-risk groups, then predicts who may benefit from additional chemotherapy. The signature was developed using Caris' clinico-genomic datasets and machine learning to identify molecular signatures associated with treatment response. NSCLC is the most common type of lung cancer. The new AI insight aims to reduce unnecessary chemotherapy exposure whilst improving treatment outcomes through more personalised therapy decisions.

ABF Journal
Apr 6th, 2026
Caris Life Sciences secures up to $1.2B in senior credit facilities from Blue Owl and Blackstone

Caris Life Sciences has secured senior secured credit facilities totalling up to $1.2 billion from funds managed by Blue Owl Capital and Blackstone, with Blue Owl serving as administrative agent. The financing comprises a $400 million initial term loan funded at closing, a $300 million committed delayed draw term loan facility available through August 2027, and an uncommitted $500 million incremental facility. The initial term loan matures in April 2031. Interest rates are term SOFR or base rate plus an additional margin of 5.00% for term SOFR rate loans and 4.00% for base rate loans. The delayed draw facility may only be used for permitted acquisitions. The agreement includes standard covenants and requires the company to maintain minimum qualified cash of $50 million tested quarterly.

PR Newswire
Apr 2nd, 2026
Caris Life Sciences launches world's first whole genome and transcriptome tumour profiling assay for myeloid malignancies

Caris Life Sciences has launched Caris ChromoSeq, described as the world's first whole genome and whole transcriptome tumour profiling assay for myeloid malignancies. The test is designed for acute myeloid leukaemia, myelodysplastic syndromes and myeloproliferative neoplasms. The assay delivers approximately 250x read depth across the genome with 40 million transcriptome reads from bone marrow aspirate or peripheral blood samples. It consolidates multiple diagnostic tests into a single seven-day turnaround assessment, aiming to expedite treatment decisions for genetically complex myeloid cancers. The Irving, Texas-based precision medicine company positions ChromoSeq as an integrated genomic solution that simplifies the myeloid diagnostic workflow whilst providing comprehensive mutation, structural variant and chromosomal abnormality detection in a single, actionable report.

PR Newswire
Mar 26th, 2026
Caris Life Sciences adds AI brain metastases risk predictions for breast and lung cancer

Caris Life Sciences has added two AI-powered signatures to its Molecular Tumour Board Report that predict brain metastases risk in breast and lung cancer patients. The signatures bring the total number of proprietary Caris AI Insights to seven. The algorithms were trained on 12,994 non-small cell lung cancer cases and 3,371 breast cancer cases with matched survival outcomes. They generate personalised predictive scores using whole exome and whole transcriptome sequencing data, helping clinicians identify high-risk patients for proactive monitoring. The insights are powered by Caris's CodeAI platform, which contains data from over 500,000 patients tested with whole exome and whole transcriptome sequencing. The technology is available through MI Cancer Seek, which received FDA approval in November 2024 as the first simultaneous sequencing-based companion diagnostic for solid tumours.

PR Newswire
Mar 25th, 2026
Caris Life Sciences to present six oncology studies utilizing proprietary multimodal data at the AACR Annual Meeting 2026.

Caris Life Sciences to present six oncology studies utilizing proprietary multimodal data at the AACR Annual Meeting 2026. Mar 25, 2026, 08:30 ET IRVING, Texas, March 25, 2026 /PRNewswire/ - Caris Life Sciences(R)(NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the Caris Precision Oncology Alliance(R)(Caris POA(R) and collaborators from leading cancer centers, will collectively present six studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California to be held April 17-22, 2026. These studies leveraged Caris' robust multimodal database, which integrates Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), immunohistochemistry (IHC) and real world clinical data, to generate clinically meaningful insights across multiple tumor types. This research reflects Caris' commitment to advancing precision oncology through deep molecular interrogation. The studies focused on breast, prostate, lung and colorectal cancers represent a collaborative effort between Caris and leading cancer centers and institutions, underscoring the power of large-scale, real world molecular evidence to accelerate discovery and improve patient outcomes. "These studies demonstrate the transformative potential of multimodal molecular data to uncover clinically meaningful patterns that would otherwise remain hidden," said James Hamrick, MD, MPH, Chairman of the Caris POA. "By combining deep genomic profiling with real world clinical evidence, Caris and its collaborators are generating insights that can directly inform treatment decisions and accelerate the development of more effective therapies for patients." Posters Include: * Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triple-negative breast cancer Session: Spatial Proteomics and Transcriptomics 1 Sunday, April 19, 2026, 2:00 PM - 5:00 PM PST Poster #: 1200/1 Location: Poster section 47 * Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC Session: Biomarkers Predictive of Therapeutic Benefit 3 Monday, April 20, 2026, 9:00 AM - 12:00 PM PST Poster #: 2434/4 Location: Poster section 40 * AR copy number amplification and AR/KLK3 expression patterns reveal mechanisms of AR signaling inhibitor (ARSI) resistance and highlight the need for AR-directed therapeutic innovation in metastatic castration resistance prostate cancer (mCRPC) Session: Molecular Targeted Therapy Monday, April 20, 2026, 2:00 PM - 5:00 PM PST Poster #: 3910/16 Location: Poster section 47 * cBioPortal for cancer genomics Session: AACR Project GENIE: Genomic Characterization Tuesday, April 21, 2026, 9:00 AM - 12:00 PM PST Poster #: 4097/2 Location: Poster section 1 * Distinct KRAS mutation codons differentially associate with microsatellite instability in colorectal carcinoma Session: Precision Oncology and Real World Data Tuesday, April 21, 2026, 9:00 AM - 12:00 PM PST Poster #: 5336/4 Location: Poster section 46 * MCM2 and the origin licensing complex: A putative node of ER+/HER2- breast cancer therapy resistance Session: Real World Data to Provide Real World Evidence Tuesday, April 21, 2026, 2:00 PM - 5:00 PM PST Poster #: 6647/16 Location: Poster section 47 Research highlights will be available onsite at Caris' booth #1423. The full abstracts will be available on the Caris website following the presentations. About Caris Life Sciences Caris Life Sciences(R)(Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Forward Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences

INACTIVE